中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.039 seconds)

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    1.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10316091B2

    公开(公告)日：2019-06-11

    申请号：US16024333

    申请日：2018-06-29

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    3.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10266595B2

    公开(公告)日：2019-04-23

    申请号：US16213960

    申请日：2018-12-07

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
    4.
    发明申请
    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING 审中-公开

    公开(公告)号：US20200308282A1

    公开(公告)日：2020-10-01

    申请号：US16827580

    申请日：2020-03-23

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
    5.
    发明申请
    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING 审中-公开

    公开(公告)号：US20190112377A1

    公开(公告)日：2019-04-18

    申请号：US16231211

    申请日：2018-12-21

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
    6.
    发明申请
    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING 审中-公开

    公开(公告)号：US20190100590A1

    公开(公告)日：2019-04-04

    申请号：US16213965

    申请日：2018-12-07

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  G01N33/574 ,  C07K16/18 ,  A61K39/395

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
    9.
    发明申请
    CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING 有权
    通过破坏PD-1 / PD-L1信号进行癌症免疫治疗

    公开(公告)号：US20150125463A1

    公开(公告)日：2015-05-07

    申请号：US14400667

    申请日：2013-05-13

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok Kumar Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  G01N33/574 ,  C07K16/18

    CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

    Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Abstract translation: 本公开提供了一种用于癌症患者的免疫治疗的方法，包括向患者施用抑制PD-1 / PD-L1信号传导途径的信号传导的Ab，或该抗体与抗CTLA-4Ab的组合。 本公开还提供了一种用于癌症患者的免疫治疗的方法，包括选择作为免疫治疗的合适候选者的患者，该评估基于来自表达细胞表面上的PD-L1的患者的来自患者的测试组织样品中细胞的比例超过 预定阈值水平，以及对所选择的受试者施用抗PD-1Ab。 本公开另外提供了与FFPE组织样品中的细胞表面表达的PD-L1抗原特异性结合的兔mAb，以及使用所提供的抗PD-L1抗体评估FFPE组织中的细胞表面表达的自动化IHC方法。

Patent Agency Ranking